CHICAGO -- The STAMP inhibitor asciminib (Scemblix) had a statistically superior response rate compared with investigator-selected tyrosine kinase inhibitors (TKIs) for patients with newly diagnosed ...

Please provide your email address to receive an email when new articles are posted on . In this video, Eric Winer, MD, discusses the results of research into chronic myeloid leukemia presented at ASCO ...

Novartis said on Monday its Scemblix was approved by the European Commission for adult patients with chronic myeloid leukemia (CML), offering a new treatment approach for patients with intolerance to ...